-
31.发明申请Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends 审中-公开通过5'末端的优化表达调节寡核苷酸类化合物的免疫刺激性质公开(公告)号：US20100254974A1
公开(公告)日：2010-10-07
申请号：US12694844
申请日：2010-01-27
申请人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
发明人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
IPC分类号： A61K39/395 , A61K39/00 , A61P37/04 , A61P37/02
CPC分类号： C07H21/04 , A61K39/39 , A61K2039/55561
摘要： The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
摘要翻译： 本发明涉及在免疫治疗应用中寡核苷酸作为免疫刺激剂的治疗用途。 更具体地，本发明提供了用于产生免疫应答的方法或用于治疗需要免疫刺激的患者的免疫
性。 本发明的免疫体包含至少两个在其3'末端连接的寡核苷酸，核苷间键或官能化核碱基或糖与非核苷酸连接体，至少一个寡核苷酸是免疫刺激性寡核苷酸并具有可接近的5'端。-
32.发明授权Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends 有权通过最优化5'末端调节基于寡核苷酸的化合物的免疫刺激性质公开(公告)号：US08202850B2
公开(公告)日：2012-06-19
申请号：US12957925
申请日：2010-12-01
申请人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
发明人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
IPC分类号： C07H21/04 , C07H21/02 , A01N43/04 , A61K39/00 , A61K39/38 , A61K45/00 , A61K47/00 , A61K31/70
CPC分类号： C07H21/04 , A61K39/39 , A61K2039/55561
摘要： The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
摘要翻译： 本发明涉及在免疫治疗应用中寡核苷酸作为免疫刺激剂的治疗用途。 更具体地，本发明提供了用于产生免疫应答的方法或用于治疗需要免疫刺激的患者的免疫
性。 本发明的免疫体包含至少两个在其3'末端连接的寡核苷酸，核苷间键或官能化核碱基或糖与非核苷酸连接体，至少一个寡核苷酸是免疫刺激性寡核苷酸并具有可接近的5'端。-
公开(公告)号：US08008267B2
公开(公告)日：2011-08-30
申请号：US10865245
申请日：2004-06-10
CPC分类号： C12N15/117 , C12N2310/17 , C12N2310/315 , C12N2310/3183 , C12N2310/321 , C12N2310/336 , C12N2310/53 , C12N2320/51 , C12N2310/3521
摘要： The invention provides immunostimulatory oligonucleotides having at least one CpG dinucleotide and a secondary structure at the 5′- or 3′-end. These oligonucleotides have either reduced or improved immunostimulatory properties. The invention establishes that 5′-terminal secondary structures affect immunostimulatory activity significantly more than those at the 3′-end. The invention also provides methods for increasing or decreasing the immunostimulatory activity of a CpG-containing nucleic acid.
摘要翻译： 本发明提供了在5'-或3'-末端具有至少一个CpG二核苷酸和二级结构的免疫刺激性寡核苷酸。 这些寡核苷酸具有降低的或改善的免疫刺激性质。 本发明确定5'-末端二级结构比3'-末端显着地影响免疫刺激活性。 本发明还提供了增加或降低含CpG的核酸的免疫刺激活性的方法。
-
34.发明授权Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends 有权通过最优化5'末端调节基于寡核苷酸的化合物的免疫刺激性质公开(公告)号：US07407944B2
公开(公告)日：2008-08-05
申请号：US10925872
申请日：2004-08-25
申请人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
发明人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
IPC分类号： A61K31/70 , A61K38/00 , A61K38/16 , A61K39/00 , A61K39/35 , A61K39/38 , A61K39/12 , A61K39/02 , A61K39/002 , A61K45/00 , A61K47/00 , A01N43/04 , A01N37/18 , C07H21/02 , C07H21/04
CPC分类号： C07H21/04 , A61K39/39 , A61K2039/55561
摘要： The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
摘要翻译： 本发明涉及在免疫治疗应用中寡核苷酸作为免疫刺激剂的治疗用途。 更具体地，本发明提供了用于产生免疫应答的方法或用于治疗需要免疫刺激的患者的免疫
性。 本发明的免疫体包含至少两个在其3'末端连接的寡核苷酸，核苷间键或官能化核碱基或糖与非核苷酸连接体，至少一个寡核苷酸是免疫刺激性寡核苷酸并具有可接近的5'端。-
公开(公告)号：US20080152662A1
公开(公告)日：2008-06-26
申请号：US11906781
申请日：2007-10-03
申请人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
发明人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
CPC分类号： C07H21/04 , A61K39/39 , A61K2039/55561
摘要： The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
-
36.发明申请MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES 失效通过使用改性免疫球蛋白来调节基于寡核苷酸的化合物的免疫学性质公开(公告)号：US20110150863A1
公开(公告)日：2011-06-23
申请号：US12952863
申请日：2010-11-23
申请人： Sudhir Agrawal , Lakshmi Bhagat , Dong Yu , Ekambar R. Kandimalla
发明人： Sudhir Agrawal , Lakshmi Bhagat , Dong Yu , Ekambar R. Kandimalla
IPC分类号： A61K39/395 , A61K31/7088 , A61K39/00 , A61K39/35 , A61K31/713 , A61K38/00 , A61K47/46 , A61P35/00 , A61P11/00 , A61P29/00 , A61P17/00 , A61P37/08 , A61P11/06
CPC分类号： C12N15/117 , C07H21/00 , C07H21/02 , C07H21/04 , C12N15/111 , C12N2310/17 , C12N2310/33 , C12N2310/3519 , C12N2310/51
摘要： The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5′ end.
摘要翻译： 本发明涉及在免疫治疗应用中寡核苷酸作为免疫刺激剂的治疗用途。 更具体地，本发明提供用于产生免疫应答的方法或用于治疗需要免疫刺激的患者的免疫学和免疫刺激性寡核苷酸。 本发明的免疫原和免疫刺激寡核苷酸优选包含新的嘌呤。 根据本发明的免疫反应物还包含至少两个在其3'末端连接的寡核苷酸，核苷间键或官能化核碱基或糖与非核酸连接体，至少一个寡核苷酸是免疫调节寡核苷酸并具有可接近的5'末端 。
-
37.发明授权Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends 有权通过最优化5'末端调节基于寡核苷酸的化合物的免疫刺激性质公开(公告)号：US07812000B2
公开(公告)日：2010-10-12
申请号：US11906781
申请日：2007-10-03
申请人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
发明人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
IPC分类号： C07H21/04 , C07H21/02 , A01N43/04 , A61K39/00 , A61K39/38 , A61K45/00 , A61K47/00 , A61K31/70
CPC分类号： C07H21/04 , A61K39/39 , A61K2039/55561
摘要： The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
摘要翻译： 本发明涉及在免疫治疗应用中寡核苷酸作为免疫刺激剂的治疗用途。 更具体地，本发明提供了用于产生免疫应答的方法或用于治疗需要免疫刺激的患者的免疫
性。 本发明的免疫体包含至少两个在其3'末端连接的寡核苷酸，核苷间键或官能化核碱基或糖与非核苷酸连接体，至少一个寡核苷酸是免疫刺激性寡核苷酸并具有可接近的5'端。-
38.发明授权Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends 有权通过最优化5'末端调节基于寡核苷酸的化合物的免疫刺激性质公开(公告)号：US07517862B2
公开(公告)日：2009-04-14
申请号：US10925873
申请日：2004-08-25
申请人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
发明人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
IPC分类号： A01N43/04 , A61K31/70 , A61K39/395 , A61K39/00 , A61K39/38 , A61K39/12 , A61K39/002 , A61K39/02 , A61K39/35 , A61K39/36 , A61K47/00
CPC分类号： C07H21/04 , A61K39/39 , A61K2039/55561
摘要： The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
摘要翻译： 本发明涉及在免疫治疗应用中寡核苷酸作为免疫刺激剂的治疗用途。 更具体地，本发明提供了用于产生免疫应答的方法或用于治疗需要免疫刺激的患者的免疫
性。 本发明的免疫体包含至少两个在其3'末端连接的寡核苷酸，核苷间键或官能化核碱基或糖与非核苷酸连接体，至少一个寡核苷酸是免疫刺激性寡核苷酸并具有可接近的5'端。-
公开(公告)号：US07354907B2
公开(公告)日：2008-04-08
申请号：US10361111
申请日：2003-02-07
申请人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
发明人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
CPC分类号： C07H21/02 , A61K2039/55561
摘要： The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines.
摘要翻译： 本发明涉及免疫系统的调节。 更具体地，本发明涉及通过使用寡核苷酸衍生的化合物调节免疫系统。 本发明提供免疫刺激剂，其比现有免疫刺激性寡核苷酸便宜。 在优选实施方案中，根据本发明的免疫刺激剂可以跨物种系引起免疫刺激。
-
40.发明申请SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS 审中-公开使用免疫调节剂联合化疗药物治疗癌症的协同治疗公开(公告)号：US20120107303A1
公开(公告)日：2012-05-03
申请号：US13006860
申请日：2011-01-14
申请人： Ekambar R. Kandimalla , Sudhir Agrawal , Daqing Wang , Lakshml Bhagat , Dong Yu
发明人： Ekambar R. Kandimalla , Sudhir Agrawal , Daqing Wang , Lakshml Bhagat , Dong Yu
IPC分类号： A61K39/395 , A61P35/00 , A61K39/385 , A61K31/7088 , A61K39/00
CPC分类号： A61K39/0011 , A61K39/39558 , A61K2039/55561 , C07K16/2887 , C07K16/32 , C07K2317/24 , A61K2300/00
摘要： The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
摘要翻译： 本发明涉及免疫刺激性寡核苷酸和/或免疫组合物与化学治疗剂组合以提供协同治疗效果的治疗用途。
-
-
-
-
-
-
-
-
-
搜索结果
215 条记录 (耗时 0.039 秒)